Member Info for BuenaVista

Do not feed the troll

Correct! Until now they have been working with poorly targetted and very poorly targetted poisons.

Anyone know any diagnostics companies in India?

I think that KEYNOTE-522 ‘combo’ therapy of 5 drugs illustrates perfectly the complexity, time and associated costs of elbowing AVA6000 into the breast cancer indication in the clinic. Obviously Avacta will need a partner and, as you say, it could be any of those three, or any other pharma company wanting to muscle in, and it's looking very much like pre|CISION will be the Arnie of cancer therapy.

If AVA6000 were to replace straight doxorubicin, who can say at this stage whether all the other drugs currently used in combo therapies would be needed, or whether alternative ones would 'plug the gaps', or indeed what new combo therapies would be tried. That's what the multitude of expensive Phase 3 clinical trials will be doing, that and looking at the associated side effects profiles.

Oh Lordy! Just don't put him in charge of counting the collection.

Https://www.marketwatch.com/story/cryptocurrency-entrepreneur-who-bought-banana-art-for-6-2-million-eats-the-fruit-in-hong-kong-80422230?mod=watchlist_latest_news

Think of all the good the $5.2m plus buyer's fees could have been put to rather than a banana just to feed this guy's ego.😡

I always have the picture of LDA sat in a high back chair, waiting for the staff to bring the tea and biscuits round, and having a sudden thought about what's happening with Avacta that needs to be urgently answered.

I have a voice to text app on my phone but, tbh, it's not as good as the standard microphone on the default (Gboard) keyboard! That's because it takes a while to process the voice and if it gets overloaded it just missed bits out until it can catch up with the voice again. The problem with the standard microphone with Gboard is that if there is a silence it just stops transcribing. That wasn't an issue with the Peel Hunt interview - fortunately because there is no 'rewind' in the PH video interface.

Anyway, good luck with finding a suitable transcriber app B2H. Your transcriptions are very useful and I'm sure we can all appreciate the work you put into editing the raw text.

As regards a transcribing app, here is what the raw text from the editor microphone (the 🎙️ icon) in Notepad on my Android phone looks like. Of course it has difficulty with specialist terms such as Avacta and AVA6000 and no punctuation, but still fairly good.

Hello and welcome to another podcast by the hunt healthcare team I'm Leoni and today we will be speaking with Dr Chris coughlin CEO of a vector about the recent updates to have actors pipeline hi Chris and welcome back of actor has certainly been very busy since we last spoke about the Phase one data from Ava 6,000 with two new novel preclinical assets recently announced freshly we have Ava 61 03 could you give us a brief overview of this therapeutic Leo thanks for having me again happy to have a conversation let's take a precision medicine apart and take a look at the different components the first we talk about these as peptide drug conjugates the peptide is the key part we refer to it as a micro peptide it's only two amino acids and a chemistry cap that's attached and then that entire peptide micropeptide is actually attached and to an active anti-cancer drug there's three key points to mention about this precision peptide that we use to mask the drugs within the bloodstream so that they're not visible to normal cells the first is our peptide vines to fat in the tumor micro environment it's then cleaved by fat in the tumor micronement these two together lead to the release of the active drug right there in the tumor where it's supposed to be importantly that peptide once it's released isn't visible to the immune system I mentioned it's a micro peptide it's only two acids and so it's too small to be an epitope it's too small to be considered by the immune system to be a foreign protein other adc's other peptide drug conjugates these peptides that are larger would be subject to these not true with precision and so we avoid a series of key toxicities the immune-based toxicities with this peptide now I mentioned it's a mask the peptide that we attached to the drug now prevents that drug from entering normal cells so it's going to prevent the toxicities and again release the drug right in the tumor micro environment the second part of the new molecule 6103 is the active drug we've chosen exit why 886,000 as you mentioned we've seen some nice activity in the clinic we've learned a lot about precision through that clinical trial we've seen that with Ava 6000 it's key that the two are types that were targeting are sensitive to the drug

Thank you for this transcript B2H. Always useful to have this form as a reference source.

CC gave a pretty good overview and there is much there to talk about I'll just pick out this: "So the way that we make it for the preclinical studies is very different than the way that we have to make it according to good manufacturing practices for the clinic. That can take some time to get it right, and so those studies have just kicked off for AVA6103."

There is actually a lot behind all this. As CC said, the compound tested in animal models just needs to be 'pure enough', is made using 'test tube' chenistry and is probably made in batches as needed. The purity needs to be at a certain level and there may or may not be stability tests carries out - probably not if it is being made in batches and used fairly swiftly.

However when it comes to testing on humans in the clinic the compound has to be made to a recognised purity, which for marketted drugs is to British Pharmacopoeia (BP) quality or the American equivalent (USP). Because it will be made in bulk, and using a chemical process suitable for bulk manufacture rather than lab quantities (possible a whole lot of chemical engineering work - and patent possibilities - there to get that right), the manufacturing has to be done at a GMP-approved facility (Avacta use a company in Switzerland for AVA6000, so we were told).

Storage conditions of the raw drug compound, its formulated form (powder or solution) and any final administrable formulation (e.g. made up solution of i.v. infusion) have to be defined, which also involves stability testing done on all these forms. You may remember the very strict storage and use by requirements of Pfizer's mRNA covid-19 vaccine.

As you can imagine, all this involves a lot of work, a lot of dealing with contractors and regulatory authorities, and a lot of bureaucracy. You can see the results for marketted products in the 'How to store' section of any patient information leaflet (PIL). And that is only a tiny part of the PIL. Both rampers and FUDsters like to disregard and complain respectively about how long it takes to jump through all the hoops, cross the eyes and dot the teas with all the third parties involved in getting a drug to market. Beware of both.

I'm really pleasantly surprised by what I've found about this guy so far.

'Blind spots in modern medicine, with Dr Marty Makary' - a podcast with transcript: https://www.balance-menopause.com/menopause-library/blind-spots-in-modern-medicine-with-dr-marty-makary/

He seems to be politically neutral and have a rational scientific mind. I particularly liked this: "Makary is an advocate for disruptive innovation in medicine".

Marty Makary, a scouser: https://en.m.wikipedia.org/wiki/Marty_Makary

Thoughts?

Do not feed the troll

Do not feed the troll

This is based on the original Phase 1a clinicaltrials.gov entry which hasn't been updated since April 2023 - over 18 months ago.

The 'they' that responded in the past were the previous management.

Is the sealion still bleating on about the antics of the previous, very amateurish and essentially clueless (innot one but two industry sectors!), management?

Do not feed the troll.

Jeez guys, this is basic.

https://en.wikipedia.org/wiki/Peer_review

Peer review is done by experts who are not involved in the work. You can't peer review your own work, no matter how expert you are; that's ridiculous!!! A conference poster or oral presentation is just a presentation of your own work, open to critique true, but the critique never changes the abstract as critique would change the content of a journal article.

Look at the full length articles by Tomlinson published in journals to understand what peer review is, although not all journals do peer review and no 'newsy' publications do peer review.